Human papillomavirus types in cases of squamous cell carcinoma of head and neck in Colombia

ABSTRACT: Estimating the type-specific prevalence of human papillomavirus (HPV) in head and neck cancer (HNSCC) is helpful in predicting the impact of HPV immunization. Objective: To estimate the overall prevalence, and gender and age-specific prevalence of HPV in HNSCC. Method: This cross sectional...

Full description

Autores:
Quintero Martínez, Katherine
Giraldo Gómez, Gabriel Andrés
Uribe Ríos, Mary Luz
Baena Zapata, Armando
López Urán, Carolina
Álvarez Martínez, Efraín
Sánchez Vásquez, Gloria Inés
Tipo de recurso:
Article of investigation
Fecha de publicación:
2013
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/32146
Acceso en línea:
https://hdl.handle.net/10495/32146
Palabra clave:
Vacunas contra Papillomavirus
Papillomavirus Vaccines
Neoplasias Orofaríngeas
Oropharyngeal Neoplasms
Neoplasias de Cabeza y Cuello
Head and Neck Neoplasms
Infecciones por Papillomavirus
Papillomavirus Infections
Neoplasias Laríngeas
Laryngeal Neoplasms
Carcinoma de Células Escamosas
Carcinoma, Squamous Cell
Papillomavirus Humano 16
Human papillomavirus 16
Papillomavirus Humano 18
Human papillomavirus 18
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/
Description
Summary:ABSTRACT: Estimating the type-specific prevalence of human papillomavirus (HPV) in head and neck cancer (HNSCC) is helpful in predicting the impact of HPV immunization. Objective: To estimate the overall prevalence, and gender and age-specific prevalence of HPV in HNSCC. Method: This cross sectional retrospective study was carried out in four pathology laboratories of Medellin, Colombia. HPV testing was performed by GP5+/6+ PCR-based RLB and HPV 16 and 18 type-specific PCR. Results: 175 primary HNSCC cases consecutively diagnosed between 1999 and 2008 with confirmed diagnosis and amplifiable DNA were included. Overall HPV prevalence was 18.9%. HPV was found in 23.9%, 17.5% and 13.3% of the oral cavity, larynx and oropharynx cases respectively. Among HPV positive cases, 82% were HPV 16 and 18% were HPV 18. No other HPV genotypes were identified. Most patients were males. Male patients were younger that their female counterparts, particularly in oral cavity cancer cases. Conclusion: HPV 16 and 18 genotypes were found in nearly 20% of HNSCC cases in Colombian patients. The impact of HPV vaccination for the prevention of HNSCC in this population deserves further evaluation.